Subtyping limited stage small cell lung cancer (LS SCLC) reveals inflammatory subtypes with improved chemoradiotherapy outcomes.
Rafael Oliveira, Tarje Halvorsen, Kristin Killingberg et al.
✦ AI-curated · Sources linked
In 30 seconds
This molecular subtype analysis examined baseline tumor gene-expression samples from participants in a randomized trial of concurrent chemoradiotherapy for limited-stage small cell lung cancer (LS SCLC). The parent trial compared two thoracic radiotherapy schedules with platinum-etoposide; subtype associations with time to progression (TTP) and overall survival (OS) were assessed in a subset. In univariable analyses, inflamed neuroendocrine tumors were associated with longer TTP (HR 0.10, 95 % CI 0.01-0.80, p = 0.03), while inflamed non-neuroendocrine tumors were associated with improved OS (HR 0.16, 95 % CI 0.03-0.77, p = 0.02).
Key findings
- SCLC-I-NE was associated with longer TTP (HR 0.10, 95 % CI 0.01-0.80, p = 0.03).
- SCLC-I-nNE was associated with improved OS (HR 0.16, 95 % CI 0.03-0.77, p = 0.02).
- SCLC-N was associated with shorter TTP (HR 6.90, 95 % CI 1.49-31.92, p = 0.01) and OS (HR 4.89, 95 % CI 1.24-19.21, p = 0.02).
Why it matters
The findings suggest that molecular subtypes may distinguish groups with different outcomes among patients receiving chemoradiotherapy for LS SCLC. This adds evidence about the potential clinical relevance of tumor subtyping in limited-stage disease, an area the authors note has been less studied than systemic treatment of extensive-stage SCLC. The associations may help inform future research into risk stratification.
What to keep in mind
Subtype-outcome associations were assessed in a subset of participants from the randomized trial and reported as univariable analyses; the study does not establish that subtype caused differences in outcome.